WO2005007070A3 - Stable pharmaceutical composition - Google Patents
Stable pharmaceutical composition Download PDFInfo
- Publication number
- WO2005007070A3 WO2005007070A3 PCT/BR2004/000119 BR2004000119W WO2005007070A3 WO 2005007070 A3 WO2005007070 A3 WO 2005007070A3 BR 2004000119 W BR2004000119 W BR 2004000119W WO 2005007070 A3 WO2005007070 A3 WO 2005007070A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administration
- protease inhibitors
- hiv protease
- pharmaceutical composition
- stable pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0302523-3 | 2003-07-23 | ||
BR0302523-3A BR0302523A (en) | 2003-07-23 | 2003-07-23 | Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005007070A2 WO2005007070A2 (en) | 2005-01-27 |
WO2005007070A3 true WO2005007070A3 (en) | 2005-03-03 |
Family
ID=37719699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2004/000119 WO2005007070A2 (en) | 2003-07-23 | 2004-07-19 | Stable pharmaceutical composition |
Country Status (2)
Country | Link |
---|---|
BR (1) | BR0302523A (en) |
WO (1) | WO2005007070A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
WO2012010942A2 (en) | 2010-07-22 | 2012-01-26 | Lupin Limited | Novel pharmaceutical composition(s) of hiv protease inhibitor(s) |
WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
GB201808564D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Treatments |
GB201907305D0 (en) * | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
-
2003
- 2003-07-23 BR BR0302523-3A patent/BR0302523A/en not_active IP Right Cessation
-
2004
- 2004-07-19 WO PCT/BR2004/000119 patent/WO2005007070A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
BR0302523A (en) | 2005-04-05 |
WO2005007070A2 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005065185A3 (en) | Temperature-stable formulations, and methods of development thereof | |
HK1080364A1 (en) | Oral pharmaceutical forms of liquid drugs having improved bioavailability | |
WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
RS77904A (en) | Oral administration form for difficulty soluble basic active ingredients which are applied orally | |
WO2007009806A3 (en) | Solid dosage formulations of narcotic drugs having improved buccal adsorption | |
CO5560580A2 (en) | FORMULATIONS OF SUCRALOSE TO DISPENSE FLAVORABLE FLAVORS | |
HUP0303891A3 (en) | Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them | |
WO2003035051A3 (en) | The use of proton sequestering agents in drug formulations | |
WO2004016277A3 (en) | Extraction of pharmaceutically active cannabinoids from plant materials | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO1999033792A3 (en) | Prodrugs os aspartyl protease inhibitors | |
MXPA05012821A (en) | Pharmaceutical formulation comprising a water-insoluble active agent. | |
CA2271196A1 (en) | Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability | |
AU2003270255A1 (en) | Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve | |
WO2006072070A3 (en) | Pharmaceutical formulations of gallium salts | |
WO2004032866A3 (en) | Therapeutic formulations | |
WO2005007070A3 (en) | Stable pharmaceutical composition | |
WO2002015933A3 (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
WO2005065648A3 (en) | Novel drug compositions and dosage forms of topiramate | |
WO2003092655A3 (en) | Use of active ingredient mixtures with azelaic acids and glycyrrhetic acids as anti-acne agents | |
WO2006034147A3 (en) | Compositions and methods for the preparation and administration of poorly water soluble drugs | |
MXPA05006528A (en) | Process for preparing combination pharmaceutical formulations using supercritical fluids. | |
WO2004071156A3 (en) | Use of edible acid in fast-dispersing pharmaceutical solid dosage forms | |
AU2003296602A1 (en) | Quaternary compounds comprising propolis as the active substance | |
WO2005013935A3 (en) | Composition for releasing a weak base for an extended period of time |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |